# Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Canonical URL: https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-long-term-efficacy-and-safety-data-for-plozasiran-across-a-spectrum-of-hypertriglyceridemia-at-the-american-college-of-cardiology-s-75th-annual-scientific-session-and-expo
Ticker: ARWR
Company: Arrowhead Pharmaceuticals
Source: Arrowhead Pharmaceuticals
Published: 2026-03-28 14:30 EST
Original Source URL: https://ir.arrowheadpharma.com
## Summary

– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis – No adjudicated acute pancreatitis events occurred in any patient

## Article Body
– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis – No adjudicated acute pancreatitis events occurred in any patient
## Recent Company News
- 2026-07-22 11:30 EST — [Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-topline-results-from-phase-3-shasta-3-and-shas-fca7dc05) — Source: Arrowhead Pharmaceuticals
- 2026-07-21 11:30 EST — [Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-third-quarter-results-94b47bc2) — Source: Arrowhead Pharmaceuticals
- 2026-06-22 16:33 EST — [Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-receives-marketing-authorization-in-the-european-union-84b496ff) — Source: Arrowhead Pharmaceuticals
- 2026-06-18 11:30 EST — [Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-host-a-webinar-on-its-cardiometabolic-pipeline-as-p-23e46e93) — Source: Arrowhead Pharmaceuticals
- 2026-06-02 11:30 EST — [Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-participate-in-upcoming-june-2026-events) — Source: Arrowhead Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)